NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the M-Vest Advances in Mental Health, Psychedelic and Non-Psychedelic Virtual Conference on September 22nd and the Cantor Virtual Global Healthcare Conference, September 27th-30th, 2021.
M-Vest Advances in Mental Health, Psychedelic and Non-Psychedelic Virtual Conference
Raj Mehra, Ph.D., Chairman and CEO will participate in a Depression Panel titled: "Spravato opened the door, what comes next?", on Wednesday, September 22nd at 2:00pm ET.
The panel discussion will be moderated by Jason McCarthy, Ph.D., Head of Biotechnology Research at Maxim Group.
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.